These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16794315)

  • 1. Iejimalides show anti-osteoclast activity via V-ATPase inhibition.
    Kazami S; Muroi M; Kawatani M; Kubota T; Usui T; Kobayashi J; Osada H
    Biosci Biotechnol Biochem; 2006 Jun; 70(6):1364-70. PubMed ID: 16794315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iejimalide C is a potent V-ATPase inhibitor, and induces actin disorganization.
    Kazami S; Takaine M; Itoh H; Kubota T; Kobayashi J; Usui T
    Biol Pharm Bull; 2014; 37(12):1944-7. PubMed ID: 25451843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.
    Niikura K; Takano M; Sawada M
    Br J Pharmacol; 2004 Jun; 142(3):558-66. PubMed ID: 15148249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
    Qin A; Cheng TS; Pavlos NJ; Lin Z; Dai KR; Zheng MH
    Int J Biochem Cell Biol; 2012 Sep; 44(9):1422-35. PubMed ID: 22652318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the osteoclast V-ATPase by small interfering RNAs.
    Hu Y; Nyman J; Muhonen P; Väänänen HK; Laitala-Leinonen T
    FEBS Lett; 2005 Sep; 579(22):4937-42. PubMed ID: 16115623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific biological functions of vacuolar-type H(+)-ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts.
    Sahara T; Itoh K; Debari K; Sasaki T
    Anat Rec A Discov Mol Cell Evol Biol; 2003 Feb; 270(2):152-61. PubMed ID: 12524690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of osteoclast vacuolar H(+)-ATPase.
    Farina C; Gagliardi S
    Curr Pharm Des; 2002; 8(23):2033-48. PubMed ID: 12171517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.
    Xu J; Cheng T; Feng HT; Pavlos NJ; Zheng MH
    Histol Histopathol; 2007 Apr; 22(4):443-54. PubMed ID: 17290355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concanamycin and indolyl pentadieneamide inhibitors of the vacuolar H+-ATPase bind with high affinity to the purified proteolipid subunit of the membrane domain.
    Whyteside G; Meek PJ; Ball SK; Dixon N; Finbow ME; Kee TP; Findlay JB; Harrison MA
    Biochemistry; 2005 Nov; 44(45):15024-31. PubMed ID: 16274249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
    David P; Nguyen H; Barbier A; Baron R
    J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
    Nyman JK; Väänänen HK
    Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. V-ATPases and osteoclasts: ambiguous future of V-ATPases inhibitors in osteoporosis.
    Duan X; Yang S; Zhang L; Yang T
    Theranostics; 2018; 8(19):5379-5399. PubMed ID: 30555553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific inhibitors of vacuolar H(+)-ATPase trigger apoptotic cell death of osteoclasts.
    Okahashi N; Nakamura I; Jimi E; Koide M; Suda T; Nishihara T
    J Bone Miner Res; 1997 Jul; 12(7):1116-23. PubMed ID: 9200012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Bafilomycin A1: an inhibitor of vacuolar H (+)-ATPases on endocytosis and apoptosis in RAW cells and RAW cell-derived osteoclasts.
    Xu J; Feng HT; Wang C; Yip KH; Pavlos N; Papadimitriou JM; Wood D; Zheng MH
    J Cell Biochem; 2003 Apr; 88(6):1256-64. PubMed ID: 12647307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding assays of inhibitors towards selected V-ATPase domains.
    Fernandes F; Loura LM; Fedorov A; Dixon N; Kee TP; Prieto M; Hemminga MA
    Biochim Biophys Acta; 2006 Nov; 1758(11):1777-86. PubMed ID: 16996024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
    Niikura K; Takeshita N; Takano M
    J Bone Miner Res; 2005 Sep; 20(9):1579-88. PubMed ID: 16059630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a new chondropsin class of antitumor compound that selectively inhibits V-ATPases.
    Bowman EJ; Gustafson KR; Bowman BJ; Boyd MR
    J Biol Chem; 2003 Nov; 278(45):44147-52. PubMed ID: 12944415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the inhibitory effect of highly potent and selective archazolides binding to the vacuolar ATPase.
    Dreisigacker S; Latek D; Bockelmann S; Huss M; Wieczorek H; Filipek S; Gohlke H; Menche D; Carlomagno T
    J Chem Inf Model; 2012 Aug; 52(8):2265-72. PubMed ID: 22747331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of inhibitors of the vacuolar H(+)-ATPase with the transmembrane Vo-sector.
    Páli T; Whyteside G; Dixon N; Kee TP; Ball S; Harrison MA; Findlay JB; Finbow ME; Marsh D
    Biochemistry; 2004 Sep; 43(38):12297-305. PubMed ID: 15379568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A plant proton-pumping inorganic pyrophosphatase functionally complements the vacuolar ATPase transport activity and confers bafilomycin resistance in yeast.
    Pérez-Castiñeira JR; Hernández A; Drake R; Serrano A
    Biochem J; 2011 Jul; 437(2):269-78. PubMed ID: 21612578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.